MonitoringCareful monitoring of treatment cycles using injectable gonadotropins is very important. This is because the normal control relationships between the follicles developing in the ovary and the pituitary gland are bypassed when follicle-stimulating hormone (FSH) and, at times when indicated, luteinizing hormone (LH), are given directly. The goal of monitoring is to make sure that optimal and sufficient, but not excessive, stimulation is being provided to the developing follicles. Most cycles are monitored with a combination of ultrasounds (to determine the number and size of the developing follicles) and blood work (to measure the estrogen being produced). The results of this monitoring, along with knowing the duration of the stimulation and your medical history, allow your doctor to determine the optimal dosage to administer. He/she can then determine when the follicles are mature and ready to ovulate. A mid-cycle LH surge is required to induce the final maturational changes in the egg, to release the egg from the wall of the follicle, and to stimulate the actual release of the egg from the follicle. In order to best time when the LH surge is to occur, "surrogate" LH surge may be provided by the injection of human chorionic gonadotropin (hCG). hCG has the same stimulatory effects on the ovary that LH does, but has a longer duration of action and is therefore more practical and effective. Related Links Follistim® AQ (follitropin beta injection) is approved to help women who have problems with ovulation. Follistim® AQ will not help women whose ovaries do not work at all (primary ovarian failure). Follistim® AQ is also for women that are in an assisted reproductive technology (ART) program, such as in vitro fertilization. Important Safety Information: Always follow your health care professional’s dosing instructions when administering Follistim® AQ Cartridge. Your health care professional has individualized the dose to be administered based on your medical history. Do not change your dose unless instructed by your health care professional. Do not use Follistim® AQ if you are allergic to recombinant human FSH products; have primary ovarian failure (your ovaries do not work at all); are pregnant or think you might be pregnant; have uncontrolled thyroid or adrenal gland problems; have tumors in your ovaries, breasts, uterus, hypothalamus, or pituitary gland; have heavy or irregular vaginal bleeding and the cause is not known; have ovarian cysts or enlarged ovaries not due to polycystic ovary syndrome (PCOS); or are allergic to streptomycin or neomycin. Follistim® AQ may contain traces of these antibiotics and may cause allergic reactions. Follistim® AQ may cause ovarian hyperstimulation syndrome (OHSS), which is a serious medical problem that can happen when the ovaries are overstimulated. In rare cases it has caused death. OHSS causes fluid to build up suddenly in the stomach and chest areas. OHSS may occur after treatment with Follistim® AQ. Call your health care professional right away if you get any of the following symptoms: severe pelvic pain (lower stomach area), nausea, vomiting, sudden weight gain, or reduced urine output. Follistim® AQ and other FSH products may cause serious lung problems including fluid in the lungs, trouble breathing, and worsening of asthma. Follistim® AQ and other FSH products may also cause blood clots in blood vessels. This can lead to blood vessel problems (thrombophlebitis), stroke, loss of limb, or a blood clot in the lung (pulmonary embolus). Follistim® AQ and other FSH products can cause multiple births. Your health care professional will discuss your chances of multiple births. Follistim® AQ should only be prescribed by physicians experienced in infertility treatments. Other side effects with Follistim® AQ include stomach pain, gas, pelvic pain, nausea, breast pain, injection site problems, enlarged stomach area, back pain, constipation, headache, and ovarian pain. If you get any side effects that concern you, call your health care professional. These are not all the side effects of Follistim® AQ. Contact your doctor or other health care professional without delay if you are experiencing symptoms including significant abdominal pain or if symptoms develop some days after the last injection has been given. Please click here for important Product Information on Follistim® AQ Cartridge. Please click here for important Product Information on Follistim® AQ Vial. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. Pregnyl® (chorionic gonadotropin for injection, USP) is approved to induce ovulation and pregnancy in women who have problems with ovulation and who have been appropriately pretreated with human menopausal gonadotropins (medications containing follicle-stimulating hormone [FSH] and luteinizing hormone [LH]). Pregnyl® will not help women whose ovaries do not work at all (primary ovarian failure).
Important Safety Information:
Pregnyl® should be used in conjunction with human menopausal gonadotropins. Pregnyl® should only be prescribed by physicians experienced in infertility treatments. Pregnyl® may cause ovarian hyperstimulation syndrome (OHSS), which is a serious medical problem that can happen when the ovaries are overstimulated. In rare cases it has caused death. OHSS causes fluid to build up suddenly in the stomach and chest areas. OHSS may occur after treatment with Pregnyl®. Call your health care professional right away if you get any of the following symptoms: severe pelvic pain (lower stomach area), nausea, vomiting, sudden weight gain, or reduced urine output. Pregnyl® may also cause rupture of ovarian cysts resulting in internal bleeding (hemoperitoneum), multiple births, and artery blockage by a blood clot (arterial thromboembolism). Other side effects with Pregnyl® include headache, irritability, restlessness, depression, fatigue, edema, and pain at the site of injection. If you get any side effects that concern you, call your health care professional. Please click here for important Product Information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. Ganirelix Acetate Injection is approved for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Important Safety Information:
Ganirelix Acetate Injection should only be prescribed by physicians experienced in infertility treatments. Before starting treatment with Ganirelix, pregnancy must be excluded. Hypersensitivity (allergic) reactions, some severe, have been reported after the first dose of Ganirelix Acetate Injection. Call your health care professional right away if you get any of the following symptoms: hives, difficulty breathing, chest tightness, high or low blood pressure, vomiting, or diarrhea. The packaging of this product contains natural rubber latex which may cause allergic reactions. Ganirelix Acetate Injection may cause ovarian hyperstimulation syndrome (OHSS), which is a serious medical problem that can happen when the ovaries are overstimulated. In rare cases it has caused death. OHSS causes fluid to build up suddenly in the stomach and chest areas. Call your health care professional right away if you get any of the following symptoms: severe pelvic pain (lower stomach area), nausea, vomiting, sudden weight gain, or reduced urine output. Other side effects with Ganirelix Acetate Injection include abdominal pain, death of unborn child, headache, vaginal bleeding, injection site reaction, and nausea. If you get any side effects that concern you, call your health care professional. Please click here for important Product Information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. |
|